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To study biometric and structural ocular manifestations of Marfan syndrome (MFS).
Methods
Observational, retrospective, comparative cohort study in a tertiary referral center on 285
MFS patients and 267 controls. Structural and biometric ocular characteristic were
compared.
Results
MFS eyes were longer (axial length 24.25 ± 1.74 mm versus 23.89 ± 1.31 mm, p < 0.001)
and had a flatter cornea than control eyes (mean keratometry 41.78 ± 1.80 diopters (D) ver-
sus 43.05 ± 1.51 D, p < 0.001). Corneal astigmatism was greater and the central cornea was
thinner in MFS eyes (530.14 ± 41.31 μm versus 547.02 ± 39.18 μm, p < 0.001). MFS eyes
were more myopic than control eyes (spherical equivalent -2.16 ± 3.75 D versus -1.17 ± 2.58
D, p < 0.001). Visual acuity was reduced (0.13 ± 0.25 logMAR versus 0.05 ± 0.18 logMAR,
p < 0.001) and intraocular pressure was lower in MFS eyes (14.6 ± 3.4 mmHg versus 15.1 ±
3.2 mmHg, p = 0.01). Iris transillumination defects (ITD) were significantly more common in
MFS eyes (odds ratio for MFS in the presence of ITD, 3.7). Ectopia lentis (EL) was only pres-
ent in MFS eyes (33.4%). History of retinal detachment was significantly more common in
MFS eyes. Glaucoma was equally common in both groups.
Conclusions
ITD and EL are most characteristic findings in MFS. ITD and corneal curvature should be
studied as diagnostic criteria for MFS. Visual acuity is reduced in MFS. MFS patients need
regular eye exams to identify serious ocular complications.
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Introduction
Marfan syndrome (MFS), an autosomal dominant connective tissue disorder, is caused by
mutations in the fibrillin-1 gene (FBN1).[1, 2] Fibrillin-1 is a major constituent of microfibrils,
involved in elastic fiber formation.[3] Manifestations of MFS affect multiple organ systems
including skeletal muscle, skin, the cardiovascular system (e.g. aortic dissection) and the eye.
[4] Up to 54% of MFS patients have major ocular involvement,[5] and ocular findings may be
crucial in establishing the diagnosis.
Diagnostic criteria were last updated in 2010 (Ghent 2 criteria).[6] In these criteria, ectopia
lentis (EL) is a cardinal diagnostic feature. Other diagnostic ocular findings are down-slanting
palpebral fissures, enophthalmos and myopia 3 diopters (D). Increased axial length (> 23.5
mm), flat cornea (< 41.5 D average corneal curvature), iris transillumination defects (ITD)
and retinal detachment (RD) are common in MFS but not part of the Ghent 2 criteria.
Although descriptive studies on ocular manifestations of MFS are available, most are
smaller series[7–10] focusing on biometric or structural findings without including a control
group.[7, 8, 10]
To better define the ocular manifestations of MFS and to study which parameters may be of
diagnostic value, we analyzed ocular biometric and structural findings in a large cohort of
MFS patients and compared them to a control group.
Materials and methods
Study population
Records of patients presenting to the interdisciplinary Marfan clinic at Charite´-Unversity
Medicine Berlin over a period of four years (December 2009 to December 2013) were
reviewed. The institutional review board approved the study and waived the need for study
subjects to consent for their records to be used in this study. The data were collected and ana-
lyzed anonymously.
Diagnosis of Marfan syndrome
A complete medical and family history was obtained. Patients received a skeletal exam, a cardi-
ologic evaluation including a trans-thoracic echocardiogram, a genetic analysis and a complete
ophthalmologic exam.
MFS was diagnosed according to the revised Ghent 2 criteria.[6] Patients with MFS were
included in the study group, patients with a connective tissue disorder other than MFS were
excluded. Patients without MFS and other hereditary connective tissue disorders were
included in the control group.
Ophthalmological examination
Best-corrected visual acuity, objective refraction (Humphrey Automatic Refractor 599, Carl
Zeiss Meditec Inc., Dublin, CA, USA), and manifest refraction (if necessary) were measured.
Intraocular pressure (IOP) was measured with non-contact tonometry (NCT, Nidek NT-530,
Nidek Co. Ltd., Aichi, Japan), and confirmed with Goldmann applanation tonometry if NCT
was unreliable or outside the normal range. A slitlamp exam of the anterior segment was done
before and after pupil dilation. EL was diagnosed if the edge of the lens was visible after pupil
dilation pupil (with neosynephrine 2.5% and tropicamide 1% eye drops). Dilated fundus
examination was performed using indirect ophthalmoloscopy.
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Biometry
Central corneal thickness (CCT), axial length (AL), aqueous depth (AD, the distance between
the posterior corneal surface and anterior lens vertex), anterior chamber depth (ACD, the dis-
tance between anterior corneal vertex and anterior lens vertex), and lens thickness (LT) were
measured.
Average corneal curvature (Kmed) and corneal astigmatism (difference between maximal
and minimal corneal curvature) were assessed using keratometry. Instruments used for biome-
try were the IOL Master™ (software version V.3.01, Carl Zeiss AG, Oberkochen, Germany), the
LENSTAR LS 9001 (Haag-Streit Holding AG, Ko¨nitz, Switzerland), the ORBSCAN II1
(Bausch & Lomb, Rochester, NY, USA) and the GALILEI™ V5.2.1 (Ziemer Ophthalmic Sys-
tems AG, Port, Switzerland).
Statistical analysis
Analysis was performed with SPSS 22 (IBM, Armonk, NY, USA). Chi-square test or Fisher’s
exact test were used for categorical variables, the t-test was for continuous variables with nor-
mal distribution, the Mann-Whitney U-test for those without normal distribution. Due to eth-
ical concerns, the institutional review board (IRB) of Charite´ –University Medicine Berlin
(Campus Charite´ Mitte, Charite´platz 1, 10117 Berlin, Germany; email: ethikkommission@ch-
arite.de) does not allow us to share the patient data publicly.
Results
Study population
Of 624 patients, 285 had MFS and qualified as controls. There were 153 male and 132 female
MFS patients, and 150 male and 117 female controls. MFS patients were older (33 ± 5.8 years,
average ± standard deviation, range 1–75 years, versus 29.1 ± 14.9 years, range 3–76 years,
p = 0.003), 37 MFS patients and 36 controls were younger than 15 years.
Biometry
MFS eyes were longer than control eyes (Table 1).
MFS eyes with EL were longer than those without (24.50 ± 2.06 mm versus 24.03 ± 1.33
mm, p = 0.0007). Anterior chamber depth was reduced in MFS eyes (Table 1), but comparable
Table 1. Biometry, dimensions and refractive error of eyes of Marfan patients and control eyes.
Marfan Control P-Value
AL (mm)1 24.25 ± 1.74 23.89 ± 1.31 < 0.001
AD (mm)2 2.95 ± 0.37 3.06 ± 0.31 0.016
ACD (mm)2 3.38 ± 0.44 3.50 ± 0.38 < 0.001
LT (mm)2 4.01 ± 0.40 3.82 ± 0.42 < 0.001
Kmed (D) 41.78 ± 1.80 43.05 ± 1.51 < 0.001
AST (D) 1.23 ± 1.01 1.03 ± 0.74 0.015
CCT (micron) 530.14 ± 41.31 547.02 ± 39.18 < 0.001
SE (D)1,2 -2.16 ± 3.75 -1.17 ± 2.58 < 0.001
AL—axial length, AD—aqueous depth, ACD—anterior chamber depth, LT—lens thickness, Kmed (D)—mean corneal curvature in diopters, AST—corneal
astigmatism, CCT–central corneal thickness, SE—spherical equivalent in diopters. Values are mean ± standard deviation.
1 –eyes with a history of retinal detachment repair were excluded from analysis
2 –only phakic eyes were analyzed
https://doi.org/10.1371/journal.pone.0183370.t001
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in MFS eyes with EL than in those without (AD, 3.01 ± 0.37 mm versus 2.94 ± 0.39 mm,
p = 0.081; ACD, 3.43 ± 0.48 mm versus 3.38 ± 0.45 mm, p = 0.357). Lens thickness (LT) was
increased in MFS eyes, but comparable in MFS eyes with and without EL (p = 0.221).
Cornea
The cornea was flatter and corneal astigmatism higher in MFS eyes (Table 1). In 46.4% of MFS
patients Kmed was< 41.5 D in at least one eye, compared with 18.7% of control patients
(p< 0.001, odds ratio (OR) for MFS 3.8, 95%CI 2.5–5.6).
MFS eyes with EL had a flatter cornea (Kmed 41.13 ± 1.79 D versus 42.11 ± 1.66 D, p =
0.001) and higher corneal astigmatism (1.63 ± 1.15 D versus 1.00 ± 0.90 D, p < 0.001) than
MFS eyes without EL.
The central cornea was thinner in MFS eyes compared with control eyes (Table 1), and
thicker in MFS eyes with EL than in those without (535.99 ± 43.69 μm versus 525.31 ±
39.74 μm, p = 0.025).
Refractive error
MFS eyes were significantly more myopic than control eyes (Table 1). EL was associated with
higher myopia in MFS eyes (SE, -2.60 ± 4.78 D versus -1.76 ± 3.38 D, p< 0.001). Myopia was
more common in MFS patients and eyes. Myopic patients were more likely to have MFS
(Table 2).
Of the MFS patients with myopia > 3 D in at least one eye, 57.5% had EL. AL in MFS eyes
with myopia > 3 D was 25.21 ± 1.82 mm (25.91 ± 1.52 mm in control eyes with myopia > 3 D,
p = 0.53) and 23.82 ± 1.31 mm in MFS eyes without myopia (p< 0.001).
Visual acuity
MFS eyes had worse visual acuity (VA) than control eyes (0.13 ± 0.25 logMAR versus
0.05 ± 0.18, p< 0.001). MFS eyes with EL had worse VA than those without (0.21 ± 0.34 log-
MAR versus 0.065 ± 0.17, p< 0.001). After surgery for EL, VA was better in pseudophakic
(0.16 ± 0.19 logMAR) than in aphakic MFS eyes (0.58 ± 0.67 logMAR, p = 0.005).
Intraocular pressure
IOP was lower in MFS eyes (14.6 ± 3.4 mmHg versus 15.1 ± 3.2 mmHg in control eyes,
p = 0.01). 4.9% of MFS patients had IOP 21mmHg in at least one eye compared with 5.3%
of controls (p = 0.089), the IOP in MFS eyes with and without EL was comparable (p = 0.721).
Structural findings
Structural findings are summarized in Table 3.
For some categories, more or less than one finding was documented per patient.
Table 2. Frequencies and odds ratio for different degrees of myopia as a diagnostic criterion for Marfan syndrome. Odds ratios (OR) are adjusted
for gender and age. 95% CI = 95% confidence interval. If only one eye of a patient fulfilled the criterion, the patient was included in the respective category.
Aphakic, pseudophakic and eyes with a history of retinal detachment repair were excluded. (D = diopters).
MFS Patients Control Patients OR 95% CI
Myopia > 3 D 80 (31.4%) 45 (19.1%) 1.9 * 1.3–3.0
Myopia > 0.75 D 174 (67.4%) 113 (47.3%) 2.3 * 1.6–3.3
Statistically significant differences are marked with an asterisk.
https://doi.org/10.1371/journal.pone.0183370.t002
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Table 3. Structural ocular findings in patients with Marfan syndrome (MFS) and controls. Total = number of patients with documented findings for the
respective category, unilat. = unilateral, bilat. = bilateral.
Ocular Structure MFS Patients Controls Pathology
(normal/total) (normal/total) (MFS Patients/Controls)









Cystic bleb after trabeculectomy 2/0
Cornea 269/279 258/261 Endothelial precipitates (bilat.) 11/0
Opacities 31/11 (bilat. 2/0)
Scar (unilat.) 0/11
Unspecified keratopathy 11/11
Cornea guttata (bilat.) 3/0
Corneal transplant (unilat.) 11/0
Cornea verticillata (unilat.) 11/0
Arcus senilis (bilat.) 1/0
Krukenberg spindles (bilat.) 2/0
Anterior Chamber 277/278 260/260 Shallow anterior chamber (bilat.) 1/0




Pupil 267/273 260/267 Corectopia 34/1
Miotic pupil 2/0
Vitreous 14/21 9/9 Opacities 4/0 (bilat. 3/0)
Optic Disc 248/271 235/251 Excavation 5/6 (bilat. 4/5)
Blurred margins 3/6 (bilat. 2/5)
Tilted disc 12/11 (bilat. 9/8)
Makropapilla (bilat.) 3/3
Pale disc (unilat.) 11/0
Macula 252/272 247/257 Blunt reflex 5/6 (bilat. 4/4)
Hemorrhage (unilat.) 1/0
Unspecified maculopathy 3/1 (bilat. 2/1)
Pigmentary changes 11/3 (bilat. 6/2)
Macular hole (unilat.) 0/1
Scar (unilat. 1/1
Retina 246/272 247/257 Peripheral degeneration incl. myopic 18/7 (bilat. 12/7)
Peripheral hemorrhages (bilat.) 0/1
1. no documented cause or reason for this finding
2. Status post retinal detachment repair with silicone oil tamponade
3. eyes with previous intraocular surgery or history of retinal detachment excluded from analysis
4. Status post vitrectomy for one MFS patient, status post trabeculectomy for two others
https://doi.org/10.1371/journal.pone.0183370.t003
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ITD (in eyes without previous intraocular surgery or retinal detachment) were more com-
mon in MFS eyes than in control eyes (p< 0.001, OR for MFS in the presence of ITD was 3.7,
95%CI 2.3–6.2). ITD were more common in MFS eyes without EL (21%) compared with con-
trol eyes (7.4%, p< 0.001). ITD were mostly bilateral (81.5% MFS patients, 72.6% controls).
39/112 (34.8%) MFS eyes with ITD also had EL, compared to 77/351 (21.9%) without ITD
(p = 0.008).
Of 76 MFS patients with ITD, 2 had glaucoma, 2 had suspected glaucoma, one had sus-
pected keratoconus, one had a history of central retinal artery occlusion, one had a phthitic eye
after retinal detachment repair and one had a cataract. Of the 24 controls with ITD, one had
glaucoma, one had suspected glaucoma suspicion, two had cataracts and one had a history of
retinal detachment repair. Iridodonesis was found in MFS patients only, it was bilateral in 80%
and associated with EL in 70%.
Lens. Normal lens findings were documented in 119/277 MFS patients and 243/261 con-
trols. Thirteen MFS patients were bilaterally aphakic, one unilaterally (12 had been operated
on for EL). There was one aphakic control patient, without a history of EL. Twenty-six MFS
patients were pseudophakic (7 unilaterally, 19 bilaterally), 17 had a history of EL, in 7 the rea-
son for pseudophakia was not identified, and 2 had had cataract surgery. One control had uni-
lateral pseudophakia after cataract surgery. One MFS patient had a history of lens coloboma.
Twenty-four MFS patients (8.7%, 12 men) had cataracts, 5 of them unilaterally. Of the 16
controls (6.1%, seven men) with cataracts, 3 had unilateral cataracts. Cataracts were equally
common in both groups (p = 0.263).
Ectopia lentis. EL was only noted in MFS patients. In 2 MFS patients, clinical examina-
tion was not possible; both had a history of EL however and were counted as EL. EL was pres-
ent in 182/544 MFS eyes (33.4%). Of 101 MFS patients with EL (43 males, 36.4% of patients
with information on lens position), it was bilateral in 81. Average age of patients with EL was
30.3 ± 15.4 years versus 34.5 ± 15.8 years of those without (p = 0.341). The lens was decentered
superiorly in the majority of eyes (Table 4). One MFS patient had bilateral phakodonesis with-
out EL.
Ocular fundus. 257/272 MFS patients and 255/257 controls had bilaterally normal fundi.
Two MFS eyes had a choroidal nevus. Two highly myopic MFS patients had bilaterally "myo-
pic fundi", another male MFS patient had a “myopic fundus” in a moderately myopic eye. One
control eye had myelinated nerve fibers, another “tortuous retinal vessels”.
Retinal detachment. Ten MFS patients (3.7%, 36.4 ± 15.5 years, eight men) and two male
controls (0.8%, 9 and 55 years old) had a history of retinal detachment (RD; p = 0.026). The
risk for RD was increased in MFS patients (OR 2.81; 95%CI 1.0–22.2; p = 0.049; adjusted for
Table 4. Direction of lens subluxation in eyes of Marfan syndrome patients with ectopia lentis (n = 101
patients, 182 eyes).
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gender and age). The RD was bilateral in 6 and unilateral in 2 MFS patients. In 2 MFS patients,
information on laterality was not available. One control had bilateral and the other a unilateral
RD. Of the MFS patients with RD, 7 had EL and 6 had previous lens surgery. Visual acuity of
MFS eyes with RD was 0.61 ± 0.84 logMAR compared with 0.11 ± 0.21 of MFS eyes without
(p< 0.001). AL of MFS eyes with RD was increased (28.6 ± 3.8 mm versus 24.1 ± 1.50 mm for
MFS eyes without RD, p< 0.001).
Glaucoma. Eight MFS patients (49.6 ± 11.8 years, 4 men) had glaucoma, 4 also had EL
and 2 had a history of RD. MFS eyes with glaucoma had an insignificantly thinner cornea
(CCT, 515 ± 63 μm) than those without (530 ± 40 μm, p = 0.218). Ten MFS patients (39.6 ±
21.2 years, 7 men) were glaucoma suspects, 3 of them had EL, one had a history of RD.
Six controls (49.0 ± 14.1 years, five men) had glaucoma, one also had peripheral retinal
degenerations, glaucoma prevalence was comparable in both study groups. Five controls were
glaucoma suspects (38 ± 14.9 years, 3 men), making suspected glaucoma equally common in
both groups.
Other diagnoses. One MFS patient had a history of unilateral branch retinal vein occlu-
sion, and 2 had a history of unilateral central retinal vein occlusion. One control had trochlear
palsy, another had a persisting hyaloid artery and 2 had congenital unilateral toxoplasmosis
(one had a macular hole, the other a macular scar).
Discussion
In this study, we compare 285 MFS patients to 267 controls with regard to biometric and struc-
tural ocular findings. To our knowledge, this is the largest comprehensive study on ocular
manifestations of MFS including a control group.
Biometry
AL in MFS eyes was increased, confirming earlier studies.[7, 8, 10–12] AL of control eyes was
comparable with that of normal adults.[13–15] We confirmed that MFS eyes with EL are longer
than those without.[7, 12, 16] It is conceivable that eyes with EL were more severely affected,
which is supported by the finding that ITD and RD were more common in eyes with EL.
Despite the increased AL in MFS eyes, AD and ACD were decreased, agreeing with the
findings of Konradsen et al.[17] Although statistically significant, the difference between MFS
and control eyes was small and unlikely to have clinical importance.
MFS eyes had increased LT. Like others,[7, 17] we did not find a significant difference in
LT between MFS eyes with EL and those without. One may hypothesize that significant
changes in LT only occur in more severe degrees of EL.
Cornea
Possible reasons for reduced corneal curvature in MFS found in this and previous studies[8,
18, 19] have been discussed elsewhere.[11] Konradsen and colleagues[9] reported that 38% of
MFS eyes and 8% of control eyes had a Kmed< 41.5 D. In our study, 46.4% of MFS eyes and
19.6% of control eyes met this criterion, suggesting that corneal curvature deserves further
evaluation as a diagnostic criterion for MFS. Because a flatter cornea and increased corneal
astigmatism is associated with EL,[8] keratometry should be performed on all patients with
MFS. It should be studied if children with MFS and abnormal corneal parameters are at
increased risk to develop EL.
The central cornea thinner in MFS eyes compared to control eyes, which has been
described before.[16, 18, 19] Although not pathologic in itself, this may have clinical relevance
as a risk factor for primary open-angle glaucoma.[20] Despite decreased corneal thickness,
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keratoconus was not noted and does not seem to have an increased prevalence in MFS
patients.[11, 19]
Refractive error
Although not specific, myopia > 3 D is part of the systemic score for MFS.[6] We found that
MFS eyes were significantly more myopic than control eyes, whereas the prevalence of myopia
and the mean refractive error of controls were comparable with the general German popula-
tion.[21] Myopia> 3 D increased the likelihood for MFS almost twofold in our predominantly
Caucasian study population. The myopia was considerably milder in our MFS patients com-
pared with those of a recent study.[8] One should consider that the prevalence of myopia var-
ies markedly between races.[21, 22] Higher degrees of myopia in MFS patients should raise the
suspicion for EL and increased axial length, a risk factor for retinal complications.
Visual acuity
There are several factors contributing to the decreased visual acuity in MFS[7, 10, 16] includ-
ing EL, myopia, aphakia and retinal complications. Maumenee[11] reported a visual acuity of
20/40 (0.3 logMAR) or better in 70.5% of MFS eyes, compared with 91.8% of MFS eyes in our
study. Possible reasons for this difference include improved diagnostic and therapeutic options
today as well as different study group composition. EL is associated with reduced visual acuity
in MFS eyes.[7, 16] After surgery for EL, pseudophakic MFS eyes had better visual acuity than
aphakic MFS eyes. Apart from aphakia itself, amblyopia and more severe ocular involvement
in aphakic eyes may contribute to this finding.
Intraocular pressure
MFS eyes had lower IOP than control eyes, but the absolute difference was likely not clinically
significant. To some degree, the thinner central cornea in MFS patients may have caused
underestimation of IOP. In contrast to previous reports,[7, 16] we did not find the IOP to be
affected by EL.
Structural findings
Pathologic external, adnexal and conjunctival findings were sporadic in both groups.
Although corneal findings were more common in MFS eyes, it is difficult to draw any con-
clusions because of the low overall number in each subcategory.
Primary ITD and iridodonesis (in eyes without previous intraocular surgery) were more
common in MFS patients than in controls. Maumenee reported ITD in approximately 10% of
MFS patients,[11] which is lower than our frequency. ITD are not pathognomonic for MFS,
they can occur in pseudoexfoliation syndrome (PEX), in pigment dispersion syndrome (PDS),
after ocular surgery, trauma and in intraocular inflammation (e.g. herpetic uveitis). None of
these diagnoses were present in subjects with ITD. With an OR of 3.7, ITD should be consid-
ered as a diagnostic criterion for MFS.
Secondary iris findings such as iridectomies are not characteristic for MFS. They probably
reflect the higher number of previous intraocular surgeries in MFS eyes.
Lens. EL is a major diagnostic criterion for MFS and was highly predictive of MFS in our
study. However, it is not pathognomonic for MFS and may be associated with other disorders
including ocular trauma, infection, inflammation and tumors. Homocystinuria,[23] dominant
familial ectopia lentis and other genetic disorders may also cause EL.[24, 25]
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Our rate of EL was comparable with recent studies from Sweden[10] and the UK,[26] but
significantly lower than the 60–79% reported in earlier investigations.[7, 11, 23] Unlike other
investigators,[7] we did not categorize phakodonesis as EL. We recommend standardization of
criteria for EL, because of its importance for the diagnosis of MFS. Like previous reports,[11,
23] we found that the lens was subluxated superiorly in most eyes with EL. The pathomechan-
ism of EL in MFS has been discussed in detail elsewhere.[4, 5, 11, 27]
The prevalence of cataracts was comparable between MFS patients and controls, but MFS
patients with cataracts tended to be younger. It remains to be seen whether there is an associa-
tion between MFS and early cataracts. Pseudophakia and aphakia were significantly more
common in MFS patients than in controls. In most cases, EL was the reason for lens surgery.
Vitreous. The vitreous was most likely not systematically examined, conclusions on the
prevalence of vitreous changes are therefore problematic. Vitreous liquefaction has been
reported in MFS.[28]
Ocular fundus and retina. Myopia-related ocular fundus findings were common in MFS.
Peripheral retinal degenerative changes were noted more than twice as often in MFS eyes com-
pared to control eyes. Pigmentary macular changes may also represent findings secondary to
higher degrees of myopia in MFS eyes.
In MFS, the risk for RD was increased, in 60% of MFS patients with RD, it was bilateral. RD is
a sight-threatening complication, reflected by the decreased visual acuity in eyes with a history of
RD. The pathomechanism and treatment of RD in MFS eyes has been discussed in detail.[28–32]
While some mostly older studies reported RD in 8%[11] of MFS patients and 9–19% of
MFS eyes,[7, 23] more recent studies including this one found lower frequencies.[5, 10, 33]
Most of our MFS patients with RD had a history of EL or lens surgery. Also, MFS eyes with a
history of RD were significantly longer than MFS eyes without. We recommend regular ocular
fundus examinations for all MFS patients, particularly those with a history of EL, lens surgery
or increased AL.
Glaucoma. Decreased central corneal thickness is known risk factor for the conversion
from ocular hypertension to glaucoma.[20] Although the central cornea of MFS eyes was thin-
ner, glaucoma was not more common in than in controls. Some studies suggest that glaucoma
may be more prevalent in MFS than in the general population,[5, 34] with open-angle glau-
coma being the most common type, followed by secondary glaucoma.[34] It appears prudent
to evaluate MFS patients for glaucoma.
There are limitations to this study. First, documentation was not standardized and some-
times incomplete. Second, different instruments were used for biometry during the course of
the study, reflecting the technological progress during the study period. Although a connective
disorder was ruled out in our controls, they probably do not represent the general population.
We believe that inclusion of a control group facilitates interpretation of the findings. When
comparing our results with earlier studies, one should consider that diagnostic criteria for
MFS continue to evolve, which affects study group composition.[35] We used the current
(Ghent 2) criteria for the diagnosis of MFS.
MFS patients were older than controls. Where appropriate, statistical analysis corrected for
age. Finally, cycloplegia was not routinely documented in children in this study, a lack thereof
may have caused overestimation of myopia in some children. However, the number of MFS
patients and controls under 15 years of age was similar, so this potential effect was probably
symmetric between the groups.
In summary, MFS patients are at increased risk for myopia, EL, RD, and reduced visual
acuity. Decreased corneal curvature and ITD should be considered as diagnostic criteria. The
knowledge of ocular manifestations of MFS is essential for early detection and to avoid compli-
cations which may permanently reduce vision.
Eye manifestations in Marfan syndrome
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